The United Kingdom and the United States have reached a significant trade agreement that will keep zero tariffs on British medicine products going into the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the NHS. This move ensures that import taxes on these vital products will remain at nothing for a duration of three years.
This agreement follows recent threats to significantly raise tariffs on patented pharmaceutical products, with increases mentioned up to 100%.
"This arrangement between the United Kingdom strengthens the global environment for cutting-edge drugs and brings much-needed balance to U.S.–U.K. pharmaceutical trade," a statement noted.
Economic Impact
Drugs represent one of the Britain's biggest exports to the America, which is easily the primary destination for major British pharmaceutical firms.
Trade data show that in the one-year period to the end of September, the UK exported pharmaceutical products valued at £11.1bn to the US. This figure accounted for 17.4% of total UK exports in that span.
"This guarantee secures jobs, stimulates funding and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister stated.
Key NHS Changes
The agreement involves several key changes from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it deems new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to increase overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage drug companies must pay back to the NHS to control costs will be limited at 15%. Previously, rebates topped twenty percent.
Recent Tensions
The deal follows a ongoing row between the sector and the UK government over medicine costs and approval rates.
This friction were exacerbated by claims that US patients were paying a premium for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been directed toward American operations.
One official acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a percentage of its resources over the past decade.
